Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Barbara Fisher MD
Closed to Accrual
Lower Grade Glioma
To compare the 3-year survival of this regimen to the 3-year survival of the EORTC high-risk low-grade glioma population described by Pignatti et al.
Data for this trial is being collected via the NRG/RTOG Data Center.
Histologic proof of supratentorial WHO grade II astrocytoma, oligodendroglioma or oligoastrocytoma confirmed by central pathology review prior to registration. Patient must have at least three of the following risk factors: Age >/= 40; Largest preoperative diameter of tumor >/= 6 cm; Tumor crosses midline; Tumor subtype of astrocytoma (astrocytoma dominant); Preoperative Neurological Function Status > 1.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.